

第 4 回 厚生科学審議会 予防接種・ワクチン分科会 研究開発及び生産・流通部会 季節性インフルエンザワクチン及び新型コロナワクチンの製造株について検討する小委員会 2026（令和8）年5月26日	参考資料 5
-------------------------------------------------------------------------------------------------------------	-----------

Overview

For vaccines for use in the 2026-2027 northern hemisphere influenza season, WHO recommends the following:

Egg-based vaccines

- an A/Missouri/11/2025 (H1N1)pdm09-like virus;
- an A/Darwin/1454/2025 (H3N2)-like virus; and
- a B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus.

Cell culture-, recombinant protein- or nucleic acid-based vaccines

- an A/Missouri/11/2025 (H1N1)pdm09-like virus;
- an A/Darwin/1415/2025 (H3N2)-like virus; and
- a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.

引用元：WHO ウェブサイト

[Recommended composition of influenza virus vaccines for use in the 2026-2027 northern hemisphere influenza season](#)

Influenza A(H1N1)pdm09 egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2026-2027 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

27 February 2026 (Last updated 11 May 2026)

Candidate vaccine viruses (CVVs) antigenically like A/Missouri/11/2025 (egg-derived) - Accession number (GISAID): EPI_ISL_20066835

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Missouri/11/2025	Wild Type		CDC	CDC
	SAN-046	Classical	Sanofi	Sanofi, USA
	IVR-279	Classical	Seqirus	MHRA
A/Switzerland/6849/2025	Wild Type		FCI	MHRA
	IVR-278	Classical	Seqirus	MHRA

引用元：WHO ウェブサイト

<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

Influenza A(H3N2) egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2026-2027 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

27 February 2026 (Last updated 11 May 2026)

Candidate vaccine viruses antigenically like A/Darwin/1454/2025 (egg-derived) - Accession number (GISAID): EPI_ISL_20260622

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Darwin/1454/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia
	IVR-283	Classical	Seqirus	VIDRL, Australia
A/Darwin/1499/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia
	IVR-284	Classical	Seqirus	VIDRL, Australia
A/Darwin/1369/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia
A/Michigan/105/2025	Wild type virus		CDC, US	CDC, USA MHRA, UK
	IVR-285	Classical	Seqirus	CCDC, China* MHRA, UK
	SAN-049A	Classical	Sanofi	Sanofi
	X-463	Classical	NYMC	NYMC
A/Sichuan-Pingshan/323/2025	Wild type virus		CCDC	CCDC, China
CNIC-2601	Classical			
A/Shanghai-Huangpu/12925/2025	Wild type virus			
	CNIC-2602	Classical		
	CNIC-2602A	Classical		

*Update(s) shown in blue

引用元：WHO ウェブサイト

<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

Influenza B Victoria lineage egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2026-2027 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

27 February 2026 (Last updated 01 May 2026)

Candidate vaccine viruses antigenically like B/Tokyo/EIS13-175/2025 (egg derived) - Accession number (GISAID): EPI_ISL_20373028

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Tokyo/EIS13-175/2025	Wild type		NIID, Japan	NIID, Japan CCDC, China
B/Tokyo/EIS13-011/2025	Wild type		NIID, Japan	NIID, Japan CCDC, China
B/Perth/115/2025	Wild type		VIDRL, Australia	NIID, Japan VIDRL, Australia
B/Wisconsin/02/2026*	Wild type		CDC, USA	CDC, USA

**New CVV shown in blue*

引用元：WHO ウェブサイト

<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>